Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
AstraZeneca
Baxter
Express Scripts
Moodys

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TBO-FILGRASTIM

➤ Subscribe for complete access

« Back to Dashboard

Biosimilar Clinical Trials for tbo-filgrastim

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT01516736 ↗ Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim Completed Sandoz GmbH Phase 3 2012-03-01 The study will assess the efficacy of LA-EP2006 compared to Neulasta┬« with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
NCT01516736 ↗ Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim Completed Sandoz Phase 3 2012-03-01 The study will assess the efficacy of LA-EP2006 compared to Neulasta┬« with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
NCT01542944 ↗ TevaGastrim for Stem Cell Mobilization Sibling Donors Completed Sheba Medical Center Phase 2 2012-02-01 The aim of this study is to evaluate the efficacy of TevaGastrim which is a biosimilar version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells from normal sibling donors for allogeneic stem cell transplantation.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for tbo-filgrastim

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000626 ↗ Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease Completed Amgen Phase 2 1969-12-31 Primary: To assess the toxicity of chemotherapy with ABVD (doxorubicin / bleomycin / vinblastine / dacarbazine) when given with filgrastim ( granulocyte colony-stimulating factor; G-CSF ) in patients with underlying HIV infection and Hodgkin's disease; to observe the efficacy of ABVD and G-CSF in reducing tumor burden in HIV-infected patients with Hodgkin's disease. Secondary: To determine the durability of tumor response to ABVD plus G-CSF over the 2-year study period; to observe the incidence of bacterial and opportunistic infections in HIV-infected patients with Hodgkin's disease receiving this regimen; to document quality of life of patients receiving this regimen. Addition of granulocyte colony-stimulating factor may prevent neutropenia caused by chemotherapy, allowing more timely administration of chemotherapy and improved response.
NCT00000626 ↗ Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 Primary: To assess the toxicity of chemotherapy with ABVD (doxorubicin / bleomycin / vinblastine / dacarbazine) when given with filgrastim ( granulocyte colony-stimulating factor; G-CSF ) in patients with underlying HIV infection and Hodgkin's disease; to observe the efficacy of ABVD and G-CSF in reducing tumor burden in HIV-infected patients with Hodgkin's disease. Secondary: To determine the durability of tumor response to ABVD plus G-CSF over the 2-year study period; to observe the incidence of bacterial and opportunistic infections in HIV-infected patients with Hodgkin's disease receiving this regimen; to document quality of life of patients receiving this regimen. Addition of granulocyte colony-stimulating factor may prevent neutropenia caused by chemotherapy, allowing more timely administration of chemotherapy and improved response.
NCT00000801 ↗ Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tbo-filgrastim

Condition Name

Condition Name for tbo-filgrastim
Intervention Trials
Lymphoma 214
Leukemia 192
Breast Cancer 83
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for tbo-filgrastim
Intervention Trials
Lymphoma 288
Leukemia 266
Myelodysplastic Syndromes 123
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for tbo-filgrastim

Trials by Country

Trials by Country for tbo-filgrastim
Location Trials
United Kingdom 66
Switzerland 54
Italy 50
Hungary 9
Norway 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for tbo-filgrastim
Location Trials
New York 282
California 278
Texas 271
Illinois 231
Ohio 218
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for tbo-filgrastim

Clinical Trial Phase

Clinical Trial Phase for tbo-filgrastim
Clinical Trial Phase Trials
Phase 4 16
Phase 3 167
Phase 2/Phase 3 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for tbo-filgrastim
Clinical Trial Phase Trials
Completed 682
Terminated 147
Unknown status 88
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tbo-filgrastim

Sponsor Name

Sponsor Name for tbo-filgrastim
Sponsor Trials
National Cancer Institute (NCI) 577
M.D. Anderson Cancer Center 112
Children's Oncology Group 71
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for tbo-filgrastim
Sponsor Trials
Other 1258
NIH 618
Industry 225
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Colorcon
Moodys
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.